RxDoctor Payments DataLook up a doctor →

Firas Hougeir, MD

Dermatology · Douglasville, GANPI 1023095957

Payments from drug & device makers

$3,252,443in general payments, 2019–2025

Across 3,546 payments — averaging $917.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$471K
  • Lilly USA, LLC$458K
  • LEO Pharma Inc.$442K
  • E.r. Squibb & Sons, L.L.C.$398K
  • Amgen$299K
  • AbbVie$126K
  • plus $1.1M from 42 others
$3,151in research payments, 2019–2025

Across 1 payment — averaging $3151.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K

What the payments were for

  • Consulting fees$483,41215%
  • Speaking & faculty fees$2,323,50674%
  • Grants$800%
  • Travel & lodging$259,7968%
  • Food & beverage$68,4882%
  • Education$6440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,252,443 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$855,624
Medicare patients
802
Services billed
3,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bimzelx AutoinjectorBimekizumab-Bkzx12$174,308
OtezlaApremilast26$142,066
Cosentyx Sensoready (2 Pens)Secukinumab12$87,481
AdbryTralokinumab-Ldrm17$63,692
OlumiantBaricitinib14$50,484
Clobetasol Propionate50$1,728
Ketoconazole105$1,541
Triamcinolone Acetonide145$1,358
Doxycycline Hyclate113$1,195
Metronidazole22$976
Mupirocin129$912
Betamethasone Dipropionate21$894
Hydrocortisone17$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$299,145$142,06626 claims
LEO Pharma Inc.Adbry$442,174$63,69217 claims
Lilly USA, LLCOlumiant$458,027$50,48414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.

Other dermatology in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →